top of page
Stimunity
Develops first-in-class drug targeting cGAS and using mRNA technology to stimulate innate immunity. By activating the STING pathway, this approach boosts the immune response against cancers and other pathologies, particularly in patients refractory to conventional treatments. Using virus-like particles (VLPs), this technology stimulates cytokine production and boosts immune cell response.
PSCC's entrance
Décembre 2025
Localization
FR - Île-de-France
Modality
Immunotherapy
Development status
Biotech - Lead optimization
Lauréat (s)
iLAB
bottom of page



